Clinical Trials Browser

Phase 2 × capivasertib × 30 days × Clear all

NCT02523014 2026-03-04

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

Phase 2 Recruiting

Meningioma

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT07426822 2026-02-24

SAFE-CAP

Phase 2 Not yet recruiting

Diarrhea, Exanthema